Skip to main
  1. Stocks
  2. Immuneering Corp
  3. Forecast
IMRX

Immuneering Corp (IMRX) Stock Forecast & Price Target

Immuneering Corp (IMRX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Immuneering is viewed positively because atebimetinib appears to solve a long-standing MEK-class problem: it delivers deep MAPK suppression through Deep Cyclic Inhibition while avoiding the chronic toxicity and adaptive pathway reactivation that limited earlier inhibitors. In first-line PDAC, the 55-patient cohort produced a 17.3-month median OS, 8.3-month median PFS, 36% ORR, and 82% DCR, with tolerability remaining clean enough that only anemia and neutropenia exceeded Grade 3 in more than 10% of patients and 84% of patients maintained or gained weight. That combination of differentiated biology, durable survival signal, and validation-ready Phase 3 design in approximately 510 patients, supported by about $199 million of cash and runway into 2029, underpins the bullish outlook.

Bears say

Immuneering is viewed negatively because atebimetinib’s value proposition in PDAC looks fragile: direct RAS inhibitors may move into first-line treatment first, leaving a more crowded and less differentiated market where a chemotherapy-combination must compete against more targeted, potentially better-tolerated options. The company’s clinical case also rests heavily on a small single-arm Phase 2 signal, while the Phase 3 MAPKeeper study faces risks from OS dilution, greater patient heterogeneity across 510 patients globally, and the possibility that better post-progression therapy blunts the endpoint. Fundamentally, Immuneering also has the typical biotech burden of operating losses, potential future capital raises, regulatory and manufacturing risk, and no approved products or commercial infrastructure to offset execution risk.

Immuneering Corp (IMRX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immuneering Corp and is not a guaranteed prediction by Public.com or investment advice.

Immuneering Corp (IMRX) Analyst Forecast & Price Prediction

Get the latest Immuneering Corp (IMRX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Immuneering Corp (IMRX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immuneering Corp (IMRX) Forecast

Analysts have given Immuneering Corp (IMRX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Immuneering Corp (IMRX) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immuneering Corp (IMRX)


Immuneering Corp (IMRX) Analyst Forecast & Price Prediction

Get the latest Immuneering Corp (IMRX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Immuneering Corp (IMRX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover IMRX stock data and trends